Cancer Monoclonal Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cancer monoclonal antibody deals entered into by the worlds leading biopharma companies.
The report provides a detailed understanding and analysis of how and why companies enter cancer monoclonal antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 599 cancer monoclonal antibody deals announced since 2016 including financial terms where available including links to online deal records of actual cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of cancer monoclonal antibody dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in cancer monoclonal antibody dealmaking since 2016.
Chapter 3 provides an overview of the leading cancer monoclonal antibody deals since 2016. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in cancer monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of cancer monoclonal antibody deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of cancer monoclonal antibody deals signed and announced since Jan 2016, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of cancer monoclonal antibody partnering deals signed and announced since Jan 2016. The chapter is organized by specific cancer monoclonal antibody technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in cancer monoclonal antibody deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
- Understand deal trends since 2016
- Browse cancer monoclonal antibody collaboration and licensing deals
- Benchmark analysis - identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, deal type and therapy area
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
The report provides a detailed understanding and analysis of how and why companies enter cancer monoclonal antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 599 cancer monoclonal antibody deals announced since 2016 including financial terms where available including links to online deal records of actual cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of cancer monoclonal antibody dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in cancer monoclonal antibody dealmaking since 2016.
Chapter 3 provides an overview of the leading cancer monoclonal antibody deals since 2016. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in cancer monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of cancer monoclonal antibody deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of cancer monoclonal antibody deals signed and announced since Jan 2016, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of cancer monoclonal antibody partnering deals signed and announced since Jan 2016. The chapter is organized by specific cancer monoclonal antibody technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in cancer monoclonal antibody deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Report Scope
Cancer Monoclonal Antibody Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of cancer monoclonal antibody trends and structure of deals entered into by leading biopharma companies worldwide.Cancer Monoclonal Antibody Collaboration and Licensing Deals includes:
- Trends in cancer monoclonal antibody dealmaking in the biopharma industry
- Directory of cancer monoclonal antibody deal records covering pharmaceutical and biotechnology
- The leading cancer monoclonal antibody deals by value
- Most active cancer monoclonal antibody licensing dealmakers
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Executive SummaryChapter 1 - IntroductionChapter 6 - Cancer monoclonal antibody dealmaking by technology type
Chapter 2 - Trends in cancer monoclonal antibody dealmaking
Chapter 3 - Leading cancer monoclonal antibody deals
Chapter 4 - Most active cancer monoclonal antibody dealmakers
Chapter 5 - Cancer monoclonal antibody contracts dealmaking directory
Deal directory
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 1ST Biotherapeutics
- 3D Medicines
- 3SBio
- 4D Pharma
- A*STAR Agency for Science
- Technology and Research
- Abbvie
- AbClon
- Abdul Latif Jameel Health
- ABL Bio
- Abmuno Therapeutics
- Abpro
- AbTherx
- Abveris
- Abzena
- Accord Healthcare
- Acerta Pharma
- Adagene
- Adaptimmune
- Adaptive Biotechnologies
- Adimab
- Adlai Nortye
- Aduro BioTech
- Advaxis
- Aeglea BioTherapeutics
- AffaMed Therapeutics
- Affimed Therapeutics
- Agenus Bio
- Agilent Technologies
- AIM ImmunoTech
- Ajinomoto
- Akeso Biopharma
- Akston Biosciences
- Alkyon Therapeutics
- Alligator Bioscience
- Alloy Therapeutics
- Almac Group
- Alphamab Biopharmaceuticals
- Alpine Immune Sciences
- Alvogen
- Alvotech
- ALX Oncology
- Ambrx
- Amgen
- Amneal Pharmaceuticals
- Ankyra Therapeutics
- Antengene
- Antigen Express
- Apeiron Biologics
- Aperion Biologics
- Apexigen
- Aptevo Therapeutics
- Arch Oncology
- Arcus Biosciences
- argenx
- Arovella Therapeutics
- Array Biopharma
- Ascentage Pharma
- Asher Biotherapeutics
- Asieris MediTech
- Aslan Pharma
- Astellas Pharma
- Astex Pharmaceuticals
- AstraZeneca
- Atara Biotherapeutics
- Athenex
- Atlab Pharma
- Atlante Biotech
- Atlas Antibodies
- AVEO Oncology
- Basilea Pharmaceutica
- Bavarian Nordic
- Baxalta
- Bayer
- BeiGene
- Beijing InnoCare Pharma
- BerGenBio
- Betta Pharmaceuticals
- Bio-Manguinhos/Fiocruz
- Bio-Thera Solutions
- BioAtla
- BioCity Biopharma
- Biocon
- Biocytogen
- Biodesix
- BioInvent
- BiolineRX
- BioMarker Strategies
- Biomm
- Biomunex Pharmaceuticals
- Bioncotech Therapeutics
- Biond Biologics
- BioNTech
- Biosion
- Biothera Pharmaceuticals
- Biotheus
- BioXcel
- BJ Bioscience
- Blackstone
- Boehringer Ingelheim
- Bolt Biotherapeutics
- Boston Immune Technologies and Therapeutics
- Bpifrance
- BridgeBio Pharma
- Bright Peak Therapeutics
- Bristol-Myers Squibb
- C-Bridge Capital
- California Institute for Regenerative Medicine
- Calithera Biosciences
- CanariaBio
- Cancer Focus Fund
- Cancer Prevention and Research Institute of Texas
- Cancer Research UK
- Cancer Science Institute of Singapore
- CanCure
- Candel Therapeutics
- Cantargia
- Caris Life Sciences
- CARsgen
- Cartexell
- CBT Pharmaceuticals
- Celgene
- Cellectis
- Celltrion
- Celularity
- Cend Therapeutics
- Centre for Drug Research and Development (CDRD)
- CG Oncology
- Champions Oncology
- Checkmate Pharmaceuticals
- Checkpoint Therapeutics
- Chi-Med
- Chime Biologics
- Chiome Bioscience
- Cilag AG
- Cipla
- Circio
- City of Hope Comprehensive Cancer Center
- Clinica Universidad Navarra
- Clovis Oncology
- CMAB Biopharma
- Coherus Biosciences
- Cold Genesys
- Columbia University
- Compass Therapeutics
- Compugen
- Convergent Therapeutics
- Corvus Pharmaceuticals
- Covalab
- Creative Biolabs
- Crescendo Biologics
- Crown Bioscience
- CStone Pharmaceuticals
- Cue Biopharma
- Cullinan Oncology
- Curative Biotechnology
- Curis
- Cytodyn
- Cytovation
- Daiichi Sankyo
- Debiopharm
- Department of Defense
- Diaprost
- Distributed Bio
- Dr. Reddy's Laboratories
- Dragonfly Therapeutics
- eFFECTOR Therapeutics
- EirGenix
- Eisai
- Elevar Therapeutics
- Elevation Oncology
- Elicio Therapeutics
- Eli Lilly
- ElsaLys Biotech
- Enlivex
- Enzolytics
- EpiThany
- EQRx
- Erasca
- Erasmus University Medical Center
- Essex Bio-Technology
- Eucure Biopharma
- Eurofarma
- European Union Regional Development Fund
- EUSA Pharma
- Eutilex
- Evaxion Biotech
- Everest Medicines
- Evopoint Biosciences
- Excellmab
- Exelixis
- F-Star Therapeutics
- FatiAbGen
- Five Prime Therapeutics
- FLX Bio
- Formosa Pharmaceuticals
- Forty Seven
- Fosun Kite Biotechnology
- Fosun Pharmaceutical
- Fred Hutchinson Cancer Research Center
- Fuhong Hanlin
- Fusion Pharmaceuticals
- Galaxy Biotech
- Galecto
- GBI BioManufacturing
- GC Cell
- Genentech
- Genexine
- GenFleet Therapeutics
- Genmab
- Genome and Company
- Genor Biopharma
- Genprex
- GenScript Biotech
- Georgetown University
- GI Innovation
- Gilead Sciences
- Glenmark Pharmaceuticals
- Glycotope Biotechnology
- Glythera
- Gossamer Bio
- GO Therapeutics
- Gradalis
- Gritstone Bio
- GSK
- H-Immune
- H3 Biomedicine
- Halozyme Therapeutics
- Harbour Biomed
- Heidelberg Pharma
- Henlius Biotech
- HiberCell
- HIBio
- HiFiBio
- Highlight Therapeutics
- Hikma Pharmaceuticals
- Hisun BioRay
- Hoffmann La Roche
- Hookipa Pharma
- Hualan Genetic
- Humanigen
- Hummingbird Bioscience
- Hutchison MediPharma
- Huyabio International
- Hypospray Pharma
- I-mab
- iBio
- IcanoMAB
- iDD Biotech
- IDEAYA Biosciences
- ImCheck Therapeutics
- ImClone Systems
- Immatics Biotechnologies
- Immix Biopharma
- Immune-Onc Therapeutics
- ImmuneOncia Therapeutics
- Immune Pharmaceuticals
- Immunicum
- Immunitas Therapeutics
- ImmunoChina Pharmaceuticals
- Immunocore
- ImmunoGen
- Immunome
- Immunomedics
- Immunovaccine
- Immutep
- IMPACT Therapeutics
- Imugene
- IMV
- Incyte
- Infinity Pharmaceuticals
- InflaRx
- Innate Pharma
- Innovent Biologics
- Inovio
- Inspirna
- Institut Bergonie
- Intas Pharmaceuticals
- Integral Molecular
- Intensity Therapeutics
- InxMed
- IO Biotech
- Ionova
- IONTAS
- Ipsen
- IRBM
- ISA Pharmaceuticals
- Italian Association for the Study of Pancreas
- iTeos Therapeutics
- Jacobio Pharmaceuticals
- Janssen Biotech
- Janssen Research & Development
- Jazz Pharmaceuticals
- JHL Biotech
- Jiangsu Alphamab
- Jiangsu Hansoh Pharmaceutical
- Jiangsu Hengrui Medicine
- Jiangsu Hengrui Pharmaceuticals
- Johns Hopkins University
- Jounce Therapeutics
- Junshi Biosciences
- KAHR Medical
- Kalbe Genexine Biologics
- Kelun-Biotech Biopharmaceutical
- Kineta
- Kiniksa Pharmaceuticals
- Kintor
- Kite Pharma
- Kolltan Pharmaceuticals
- Kymab
- Laekna
- Lassen Therapeutics
- Lava Therapeutics
- Leap Therapeutics
- Leica Biosystems
- LEO Pharma
- Les Laboratoires Servier
- Leukemia & Lymphoma Society
- LG Life Sciences
- LifeMax Laboratories
- Ligand Pharmaceuticals
- Linnaeus Therapeutics
- Livzon Mabpharm
- Lonza
- Lumos Pharma
- Lunit
- Lupagen
- Lyvgen Biopharma
- MAB Discovery
- mAbsolve
- mAbXience
- Macrogenics
- MAIA Biotechnology
- Manhattan BioSolutions
- Massachusetts General Hospital
- Mayo Clinic
- MD Anderson Cancer Center
- Medical Research Council
- Medicenna Therapeutics
- MediLink Therapeutics
- MedImmune
- Medison Pharma
- Memorial Sloan Kettering Cancer Center
- Merck and Co
- Merck KGaA
- Merck Sharpe & Dohme
- Mereo BioPharma
- Merrimack Pharmaceuticals
- Merus
- Microbiotica
- Mitra Biotech
- Molcure
- Moleculin Biotech
- Monopar Therapeutics
- MorphoSys
- Morphotek
- Mount Sinai Health System
- MSD
- MS Pharma
- Mundipharma
- Mustang Bio
- Mylan Pharmaceuticals
- Myriad Genetics
- Nanjing Leads Biolabs
- Nascent Biotech
- National Cancer Institute
- National Center for Tumor Diseases
- National Comprehensive Cancer Network (NCCN)
- National Institutes of Health
- National University Cancer Institute
- Navrogen
- Nectin Therapeutics
- Nektar Therapeutics
- Nelum Pharma
- NeoImmuneTech
- Neoleukin Therapeutics
- Neon Therapeutics
- NETRIS Pharma
- Neuroblastoma and Medulloblastoma Translational Research
- Nexvet
- NGM Biopharmaceuticals
- NiKang Therapeutics
- NKGen Biotech
- NKMax America
- Nona Biosciences
- Nordic Society of Gynaecological Oncology
- Nouscom
- NovalGen
- Novartis
- Novelogics Biotechnology
- Novocure
- Noxopharm
- Noxxon Pharma
- Numab
- Nykode Therapeutics
- OBI Pharma
- Olatec Therapeutics
- Olivia Newton-John Cancer Research Institute
- OncoC4
- OncoCare Therapeutics
- OncoImmune
- Oncologie
- Oncolytics Biotech
- OncoQuest
- OncoResponse
- OncoSec Medical
- OncoVerity
- Oncternal Therapeutics
- Oncurious
- OncXerna Therapeutics
- Ono Pharmaceutical
- Ordaos Bio
- OSE Immunotherapeutics
- Oxford BioTherapeutics
- Panacea Pharmaceuticals
- Pascal Biosciences
- PDS Biotechnology
- Peregrine Pharmaceuticals
- Personal Genome Diagnostics
- Personalis
- Pfizer
- Phanes Therapeutics
- PharmAbcine
- Pharmapark
- Pieris Pharmaceuticals
- Pierre Fabre
- Pionyr Immunotherapeutics
- PlantForm
- PlantPraxis Biotecnologia
- PMV Pharma
- Pneuma Respiratory
- POINT Biopharma
- Portage Biotech
- Poseida Therapeutics
- Precision BioSciences
- Prelude Therapeutics
- Prestige BioPharma
- ProBioGen
- Progenetics
- Progenics Pharmaceuticals
- Promega
- ProtoKinetix
- PT Etana Biotechnologies
- PULSALYS
- Purdue University
- PureTech Health
- Pyxis Oncology
- QBiotics
- QIAGEN
- Quantum Leap Health Care Collaborative
- Quest PharmaTech
- Qurient
- Radboud University Nijmegen Medical Centre
- RefleXion Medical
- Regeneron Pharmaceuticals
- Regnum
- RemeGen
- Replimune
- Rexahn Pharmaceuticals
- Roche
- Roswell Park Cancer Institute
- RubrYc Therapeutics
- Rxilient Biotech
- Rznomics
- Saccharo
- Samsung Bioepis
- Samsung Biologics
- Samyang Biopharmaceuticals
- Sandoz
- Sanofi
- Sanofi-Aventis
- Sarah Cannon Research Institute
- SATT Sud-Est
- Scandion Oncology
- Schrodinger
- SciClone Pharmaceuticals
- Scripps Research Institute
- Seagen
- Seattle Genetics
- Seismic Bio
- Selecxine
- Selexis
- SELLAS Life Sciences Group
- Sensei Biotherapeutics
- Seven and Eight Biopharmaceuticals
- SevenScore Pharmaceuticals
- Sharp HealthCare
- Shenogen Pharma
- Shenzhen Chipscreen Biosciences
- Simcere Pharmaceuticals
- Simcha Therapeutics
- Sirnaomics
- Sonnet BioTherapeutics
- Sorrento Therapeutics
- Sosei Heptares
- SOTIO
- Spanish National Research Council
- Specialised Therapeutics
- Specialized Medical Services-oncology
- STADA Arzneimittel
- Strata Oncology
- Sud Investments
- Surface Oncology
- Syndax Pharmaceuticals
- Synlogic
- Syros Pharmaceuticals
- T-Cure Bioscience
- Taiho
- Takeda Pharmaceutical
- Talem Therapeutics
- TARIS Biomedical
- Tavotek Biotherapeutics
- TCR2 Therapeutics
- Telix Pharmaceuticals
- Tempest Therapeutics
- TeneoBio
- Teon Therapeutics
- Tesaro
- Tessa Therapeutics
- Tetragenetics
- Teva Pharmaceutical Industries
- TG Therapeutics
- The Jackson Laboratory
- Theranyx
- Thermo Fisher Scientific
- ThromboGenics
- TILT Biotherapeutics
- Tiziana Life Sciences
- Tizona Therapeutics
- Tmunity Therapeutics
- Torque Therapeutics
- TRACON Pharmaceuticals
- Transcenta
- Transgene
- TransThera
- Trianni
- Trieza Therapeutics
- Trio Pharmaceuticals
- Triumvira Immunologics
- Turgut Ilaclari
- Twist Bioscience
- UbiVac
- UCB
- Universite Claude Bernard Lyon
- University of Bergen
- University of British Columbia
- University of California
- San Diego
- University of California Los Angeles
- University of California San Francisco
- University of Florida
- University of New Mexico
- University of Wisconsin Carbone Cancer Center (UWCCC)
- UroGen Pharma
- Vaccinex
- Vaximm
- Vcell Healthcare
- Vedanta Biosciences
- Verseau Therapeutics
- Viela Bio
- Vyriad
- Wellmarker Bio
- Werewolf Therapeutics
- Wilex
- WindMIL Therapeutics
- WuXi Biologics
- Wuxi Shuangliang Biotechnology
- Xencor
- Xilio Therapeutics
- Xoma
- Xuanzhu Biopharma
- Xyphos Biosciences
- Y-Biologics
- Y-mAbs Therapeutics
- Yale Cancer Center
- Yale University
- ZAI Laboratory
- Zenoaq
- Zhejiang Bossan Pharmaceutical
- Zhejiang Hisun Pharmaceutical
- Zhejiang Huahai Pharmaceutical
- Zydus Cadila
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
